CD33 - Wikipedia
WEBCD33 or Siglec-3 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67) is a transmembrane receptor expressed on cells of myeloid lineage. [5] It is usually considered myeloid-specific, but it can also be found on some lymphoid cells.
CD33 - an overview | ScienceDirect Topics
WEBCD33 is a type I transmembrane protein of the sialic acid-binding immunoglobulin-like lectins (SIGLECS) family and is expressed on haematopoietic and phagocytic cells including microglia [24••,25•,26• ]. CD33 regulates innate immunity, possibly Aβ clearance and other neuroinflammatory processes ( Figure 1 ).
The role of CD33 as therapeutic target in acute myeloid leukemia
WEBCD33 is a myeloid differentiation antigen that is displayed on acute myeloid leukemia (AML) blasts in most patients and, possibly, leukemic stem cells in some, and has thus served as target for antibody-based therapies for many years.
CD33-Targeted Therapies: Beating the Disease or Beaten to …
WEBGemtuzumab ozogamicin was the first and only CD33-directed antibody-drug conjugate to be US Food and Drug Administration approved for AML. Other targeted agents have not achieved such success. Promising new strategies include cellular therapy mechanisms and linker molecules.
CD33 Gene - GeneCards | CD33 Protein | CD33 Antibody
WEBAug 5, 2024 · CD33 (CD33 Molecule) is a Protein Coding gene. Diseases associated with CD33 include Cardiovascular System Disease and Growth Hormone Insensitivity Syndrome With Immune Dysregulation 2. Among its related pathways are Innate Immune System and Class I MHC mediated antigen processing and presentation.
CD33 protein expression summary - The Human Protein Atlas
WEBUseful information about the protein provided by UniProt. Sialic-acid-binding immunoglobulin-like lectin (Siglec) that plays a role in mediating cell-cell interactions and in mai ntaining immune cells in a resting state 1, 2, 3. Preferentially recognizes and binds alpha-2,3- and more avidly alpha-2,6-linked sialic acid-bearing glycans 4.
CD33 and CD33-Related Siglecs in Pathogen Recognition and
WEBApr 1, 2022 · CD33 is a myeloid differentiation marker antigen with immune functions associated with anti-inflammatory signaling, cell adhesion, and endocytosis. CD33 is expressed by the earliest myeloid progenitors and …
Distribution and levels of cell surface expression of CD33 and
WEBJun 13, 2014 · Owing to the more recent positive results with the anti-CD33 immunotoxin gemtuzumab ozogamicin, therapy against acute myeloid leukemias (AMLs) targeting CD33 holds many promises.
The past and future of CD33 as therapeutic target in acute myeloid ...
WEBCD33 is a myeloid differentiation antigen with endocytic properties. It is broadly expressed on acute myeloid leukemia (AML) blasts and, possibly, some leukemic stem cells and has therefore been exploited as target for therapeutic antibodies for many years.
CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid …
WEBJun 28, 2021 · Gemtuzumab ozogamicin (GO), a humanized murine IgG4 anti-CD33 antibody, is the first target therapy approved in AML therapeutic scenario. This review focuses on current biological information and clinical data from several studies investigating the use of GO in patients with AML.